Cadrenal Therapeutics, Inc. Common Stock (CVKD) Ownership — Insider & Political Trading

Cadrenal Therapeutics, Inc. Common Stock (CVKD) — Price $1.08 HealthcareBiotechnology — NASDAQ

Latest reported results:

Ownership and insider activity for Cadrenal Therapeutics, Inc. Common Stock (CVKD): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.

Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation.

Price

Price$1.08
Market Cap$4M
ExchangeNASDAQ
CountryUS

Balance Sheet (10y)

Year2022202320242025
Cash & Equivalents$32586$8.4M$10.0M$4.0M
Short-term Investments0000
Receivables0$37248$38153$5096
Inventory0000
Total Current Assets$727596$8.5M$10.1M$4.3M
Property, Plant & Equipment$44591$23285$6944$5174
Goodwill0000
Intangible Assets0000
Total Assets$778174$8.5M$10.1M$4.3M
Accounts Payable$404897$167319$1.5M$650663
Short-term Debt$43728000
Total Current Liabilities$1.3M$826875$2.7M$1.6M
Long-term Debt$553340000
Total Liabilities$6.3M$826875$2.7M$1.6M
Retained Earnings-$6.7M-$15.1M-$25.7M-$39.0M
Total Equity-$5.6M$7.7M$7.4M$2.7M
Total Debt$640706$2135000
Net Debt$608120-$8.4M-$10.0M-$4.0M
Working Capital-$606881$7.7M$7.4M$2.7M

Financial Health

Debt / Equity0.00
Current Ratio3.73

Profitability

Return on Equity-406.38%
Return on Invested Capital-284.81%
Return on Assets-206.55%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%

Related companies: CLGN · IBIO · ITRM · KLTO · NRSN · NRXS · RLYB

Explore sector: Healthcare · Biotechnology

More sections of CVKD: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks